Resectable Primary Tumor in Patients with Pancreatic Neuroendocrine Tumors Located to the Body or Tail and Unresectable Liver Metastases: Does Distal Pancreatectomy Improve Survival? Abstract #1348

Introduction: The role of primary tumor surgery in pancreatic neuroendocrine tumor (PNET) with unresectable liver metastases is controversial and international guidelines do not recommend surgery in that setting of patients
Aim(s): To assess whether or not distal pancreatectomy performed at diagnosis is associated with improved long-term survival for body or tail primary localizations with unresectable liver metastases
Materials and methods: From two institutional databases of patients affected by PNET and unresectable liver metastases, 30 patients with a potentially resectable but not-resected primary tumor located in the body or tail were identified and compared with a group of 63 patients who underwent a left-pancreatectomy at diagnosis. The endpoint was overall survival (OS)
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Dr Emilio Bertani

To read results and conclusion, please login ...

Further abstracts you may be interested in

#137 Extensive ""multitasking"" surgery for advanced neuroendocrine tumors is safe and effective
Introduction: Management of advanced NETs is controversial, related to degree of intervention; the pendulum is swinging towards a more aggressive interventional approach. Our Center's philosophy is to offer a systematic, planned multimodality treatment for patients with advanced NETs.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD MICHAIL K Shafir
#497 Metastatic Pancreatic Neuroendocrine Carcinoma: Does Aggressive Surgical Intervention Improve Outcome?
Introduction: Pancreatic neuroendocrine tumors (PNETS) often present late. At diagnosis, 65% of patients have metastases, with median survival of 24 months. The conventional approach is conservative management. Recent evidence has suggested that aggressive treatment leads to better outcomes.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Michael White
Keywords: pancreatic, surgery
#546 Treatment of Malignant Neuroendocrine Tumors of the Hepatopancreatododenal Region
Introduction: The incidence of malignant NETs of the hepatopancreatoduodenal region is currently set at 10-15 cases per 100,000 people. Patient treatment and prognosis differ from those with adenocarcinoma.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Ivan Vasiliev
#665 Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: Surgery is the only potential for cure in patients with pancreatic neuroendocrine tumors (pNETs).
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Esther I Van Vliet
#683 Liver Resection Experience for Metastatic Small Bowel NETs, a Single Center Experience
Introduction: Over the last two decades, the role of surgery in the management of small bowel NETs (SBNET) has evolved. There is growing evidence supporting the role of liver resection for metastatic disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Raj Srirajaskanthan